Circulating Tumor DNA Analysis From Pts With mCRC Who Were Treated With Panitumumab in ASPECCT

June 2-6, 2017; Chicago, Illinois
Next-generation sequencing of circulating tumor DNA revealed complex mutational changes with panitumumab treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 846 KB
Released: June 8, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings